Burkhard Otremba

Safety and Cost Effectiveness of a 10 × 109/L Trigger for Prophylactic Platelet Transfusions Compared With the Traditional 20 × 109/L Trigger: A Prospective Comparative Trial in 105 Patients With Acute Myeloid Leukemia

Hannes Wandt, Markus H. Frank, Gerhard Ehninger et al. · Blood · 1998 · 300 citations · Full text

Medicine, Hematology, Pharmacoeconomics +16

Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study

Élodie Elkaim, Bénédicte Neven, Julie Bruneau et al. · Journal of Allergy and Clinical Immunology · 2016 · 285 citations · Full text

Life Sciences, Immunology, Molecular Genetics +17

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

G. Huebner, Hartmut Link, C.-H. Köhne et al. · British Journal of Cancer · 2008 · 87 citations · Full text

Medicine, Oncology, Pharmacology +12

Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme

Axel Heidenreich, Hans-Jörg Scholz, Sebastian Rogenhofer et al. · European Urology · 2012 · 77 citations

Medicine, Oncology, Pharmacology +14